Peps
What is PNC-27?
PNC-27 is a laboratory peptide built from part of the p53 tumor-suppressor protein attached to a cell-penetrating sequence. It has been studied in cancer-cell cultures and animal models. It is not an approved or human-tested cancer treatment.
Biological role or research focus
Experimental cancer-cell membrane research.
One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.
Role reference: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Names you may encounter
p53-penetratin peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic chimeric peptide: an HDM-2-binding segment of p53 joined to a membrane-penetrating sequence
- Research focus
- Experimental cancer-cell membrane research
- Featured evidence
- Cell study
- Source check
- October 4, 2026
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Biology & proposed mechanism
Investigators report that PNC-27 binds HDM-2 found on the membranes of some cancer cells and forms pores that rupture them, while sparing non-cancer cells in the same experiments. These are laboratory observations about cell membranes, not evidence of tumor control in patients.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Research context & identity
This profile covers preclinical cancer biology. No completed human trials of PNC-27 were found when this page was checked. PepsRadar does not link to sellers from this page: people with cancer should rely on their oncology team, and research listings are not treatments.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Cell study · 2010
Labeled PNC-27 in breast cancer and non-cancer breast cells
What did this publication test, and what did it find?
- Population / model
- MCF-7 human breast cancer cells and untransformed MCF-10-2A breast epithelial cells in culture.
- Study design
- The peptide carried a different fluorescent label at each end so investigators could track whether it stayed intact in the membranes of cancer and non-cancer cells over time.
- Main finding
- In the cancer cells, intact peptide collected in the membrane and the cells broke apart. In the non-cancer cells, the signal faded and the cells stayed alive. The authors concluded that the whole peptide, not its fragments, causes the membrane damage.
- Limits & context
- One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Human safety is unknown. A membrane-disrupting peptide could harm normal tissue under real-world conditions, and research-grade products are not manufactured or tested as medicines.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Evidence boundaries
One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
PepsRadar does not link to sellers from this page. It is an experimental compound without human evidence, and research listings are not treatments.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is PNC-27 a cancer treatment?
- What material, population, and route were actually studied?
- One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is PNC-27 a cancer treatment?
No. It is an experimental molecule studied in cell cultures and animals. It has not been shown to treat cancer in people and should never replace care from an oncology team.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.